Tissue plasminogen activator

ApprovedSmall molecule

NNeuroscience Trials Australia

Tissue plasminogen activator is one of 297 small molecule programs targeting Stroke. It is currently in Approved.

Indications

Total Trials

Active Trials

296

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Abdominal AbscessActive, not recruiting

HemorrhageActive, not recruiting

HematomaActive, not recruiting

PeritonitisActive, not recruiting

Myocardial InfarctionActive, not recruiting

ThromboembolismActive, not recruiting

Retinal Vein OcclusionActive, not recruiting

Myocardial IschemiaActive, not recruiting

Tissue Plasminogen ActivatorNot yet recruiting

StrokePhase 2

Active, not recruiting

Abdominal AbscessPhase 2/Phase 3

Active, not recruiting

HemorrhagePreclinical

Active, not recruiting

HematomaApproved

Active, not recruiting

PeritonitisPhase 1

Active, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

ThromboembolismPreclinical

Active, not recruiting

Retinal Vein OcclusionPhase 1

Active, not recruiting

Myocardial IschemiaPhase 3

Active, not recruiting

Tissue Plasminogen ActivatorApproved

Not yet recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Tissue plasminogen activator

NNeuroscience Trials Australia

Approved

5 2

Savella

AbbVie

Preclinical

1 3

Proamatine

Pradaxa

3 5

Haldol

DDePuy Orthopaedics

Preclinical

1 6

Zantac 150

CChattem

Preclinical

1 7

Direct Anticoagulant

Bayer

Preclinical

3 8

Anticoagulant

Bayer

Preclinical

1 9

Anticoagulants

Sanofi

Preclinical

1 10

Botulinum Toxin a

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Hemorrhage

NCT05736757

Q2 2028

Phase 2/3Recruiting

Trial

NCT05766124

Q2 2029

ApprovedNot yet recruiting

Tissue Plasminogen Activator

NCT07643493

Clinical

Trials by Indication[1]

Stroke5 trials

Regisry of the Stroke Patients in Assiut University Hospital

Unknown status·—·N/A·NCT03392792·1 enrolled

Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

Completed·MMelbourne Health·Phase 2·NCT04071613·104 enrolled

A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA

Unknown status·DD-Pharm Ltd.·Phase 2·NCT02572336·40 enrolled

Show 2 more trials

EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429476·234 enrolled

Thrombolysis in Pediatric Stroke (TIPS)

Terminated·SSeattle Children's Hospital·Phase 1·NCT01591096·1 enrolled

Ischemic stroke3 trials

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

Completed·UUniversity of California, San Diego·Phase 1·NCT00283088·130 enrolled

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

Completed·NNeuroscience Trials Australia·Phase 2·NCT02388061·202 enrolled

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

Terminated·UUniversity of Virginia·Phase 2·NCT00252239·112 enrolled

Subarachnoid Hemorrhage2 trials

Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage

Unknown status·UUniversity of Calgary·Phase 2·NCT01098890·12 enrolled

Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage

Withdrawn·RRush University Medical Center·Phase 1/2·NCT01878136

Myocardial Infarction2 trials

Myocardial Infarction Triage and Intervention Project (MITI)

Completed·UUniversity of Washington·Phase 3·NCT00000468

Thrombolysis in Myocardial Infarction (TIMI)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000505

Thrombolysis2 trials

Extending the Time for Thrombolysis in Emergency Neurological Deficits

Completed·NNeuroscience Trials Australia·Phase 3·NCT00887328·180 enrolled

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

Completed·NNeuroscience Trials Australia·Phase 3·NCT01580839·45 enrolled

14 more indications

STEMI1 trial

Adjunctive, Low-dose tPA in Primary PCI for STEMI

Completed·PPopulation Health Research Institute·Phase 3·NCT03335839·210 enrolled

Myocardial Ischemia1 trial

Thrombolysis in Myocardial Ischemia Trial (TIMI III)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000472

Trial1 trial

Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)

Recruiting·—·Phase 2/3·NCT05766124·30 enrolled

CAR1 trial

Thrombolytic Care During Inter-hospital Transfer

Completed·UUniversity of Iowa··NCT02752256·76 enrolled

Hemorrhage1 trial

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05736757·20 enrolled

Hematoma1 trial

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

Completed·HHamilton Health Sciences Corporation·Phase 4·NCT05491356·40 enrolled

Prosthetic Valve Thrombosis1 trial

Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis

Completed·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT01451320·182 enrolled

Fibrinolysis1 trial

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

Suspended·—··NCT06310018·60 enrolled

Abdominal Abscess1 trial

Safety and Effectiveness of tPA in Intra-abdominal Abscesses

Terminated·UUniversity Health Network, Toronto·Phase 2/3·NCT00417768·35 enrolled

Peritonitis1 trial

The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients

Terminated·SSir Charles Gairdner Hospital·Phase 1·NCT01478698·5 enrolled

Thromboembolism1 trial

Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism

Unknown status·—··NCT05512702·100 enrolled

Acute Respiratory Distress Syndrome1 trial

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

Withdrawn·NNegovsky Reanimatology Research Institute·Phase 3·NCT04453371

Retinal Vein Occlusion1 trial

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01581411·1 enrolled